================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                           ---------------------------

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): November 9, 2005
                                                         -----------------------

                         PRESTIGE BRANDS HOLDINGS, INC.


    Delaware                        001-32433                      20-1297589
- ---------------                   ------------                   ---------------
(State or Other Jurisdiction   (Commission File Number)      (I.R.S. Employer
  of Incorporation)                                         Identification No.)

                  90 North Broadway, Irvington, New York 10533
                  --------------------------------------------
          (Address of Principal executive offices, including Zip Code)

                                 (914) 524-6810
                                 --------------
              (Registrant's telephone number, including area code)

Check the appropriate  box if the Form 8-K filing is intended to  simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions :

     [ ] Written  communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     [ ] Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     [ ]  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR.13e-4(c))

================================================================================

Item 1.01. Entry into Material Definitive Agreement. (a) On November 9, 2005, Prestige Brands, Inc. (the "Borrower")and Prestige Brands International LLC (the "Parent") entered into an Amendment No. 2 and Waiver to the Credit Agreement ("Amendment No. 2") with the Lenders and Issuers party thereto and Citicorp North America, Inc., as agent for the Lenders and Issuers, Bank of America, N.A., as syndication agent, and Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services, Inc., as documentation agent. The Borrower and the Parent are indirect wholly owned subsidiaries of Prestige Brands Holdings, Inc. Amendment No. 2, among other things, waives certain events of default and deletes future delivery requirements in each case with respect to consolidating financial statements. A specimen copy of Amendment No. 2 was filed as Exhibit 99.1 to the Company's Current Report on Form 8-K dated October 31, 2005 and filed with the Commission on November 1, 2005 and is incorporated herein by this reference. (b) On November 9, 2005, Prestige Brands Holdings, Inc. (the "Company") completed the purchase of Dental Concepts, LLC ("Dental Concepts") through an acquisition of all of its outstanding membership interests. The letter of intent with respect to that transaction previously was announced on September 19, 2005. Item 1.01 of the Company's Current Report on Form 8-K filed on September 19, 2005 is hereby incorporated by reference. The purchase price for the Dental Concepts membership interests was $30.6 million (including purchase price adjustments), which was paid through the Company's accessing its existing line of credit. On November 14, 2005, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by this reference, announcing the execution of the Dental Concepts definitive purchase agreement. Item 7.01. Regulation FD Disclosure. The information set forth in Item 1.01 above is incorporated by reference as if fully set forth herein. Item 9.01. Financial Statements and Exhibits. (a) Financial Statements. None (b) Pro Forma Financial Information. None (c) Exhibits. 99.1 Press Release dated November 14, 2005 Regarding Execution of Dental Concepts Definitive Purchase Agreement

SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 15, 2005 PRESTIGE BRANDS HOLDINGS, INC. By: /s/ Charles N. Jolly --------------------------------- Name: Charles N. Jolly Title: General Counsel

PRESTIGE BRANDS HOLDINGS COMPLETES ACQUISITION
OF DENTAL CONCEPTS, LLC

     Irvington,  New York,  November 14,  2005--Prestige  Brands Holdings,  Inc.
(PBH-NYSE)  today  announced that it has completed the purchase of the assets of
Dental  Concepts,  LLC, a marketer of  therapeutic  oral care  products  sold in
retail outlets throughout the United States and Canada.

     On September 19, 2005,  Prestige  announced it had entered into a Letter of
Intent for the purchase of all of the assets of Dental Concepts,  LLC.  Prestige
said it  expected  to close in the fall of 2005,  subject  to  confirmatory  due
diligence. The acquisition was completed on November 9, 2005 at a purchase price
of  approximately  $30.5 million.  Prestige  purchased the Company from Hamilton
Investment  Partners,  LLC, a New York  investment  firm,  and other  investors.
Sewaya Segalas & Co., LLC a leading consumer products  investment  banking firm,
served as financial advisor to Prestige on this transaction.

     The brands included in the acquisition are The Doctor's(R) Nightguard,  the
#1  over-the-counter  dental  protector for night time teeth  grinding;  and The
Doctor's(R)  Brush  Picks  and  The  Doctor's(R)   Orapik,  both  of  which  are
over-the-counter interproximal cleaning devices. Trailing twelve month net sales
for Dental Concepts were approximately  $14.8 million.  The Doctor's  Nightguard
accounts  for  more  than  half  of  the  revenue.   Prestige  anticipates  this
acquisition  will be modestly  accretive to earnings per share this fiscal year.

     Commenting on the completion of the Company's second important  transaction
this year, Peter C. Mann, Chairman and Chief Executive Officer said, "This is an
excellent  acquisition  for the Company.  We've added a growing  business to the
Prestige portfolio, one with good distribution,  and synergies in several areas.
Importantly,  we believe we can add meaningful  value to these brands and to the
Company".

     In October,  Prestige  completed  the  acquisition  of Chore  Boy(R)  brand
cleaning pads, scrubbing sponges and non-metal soap pads from Reckitt Benckiser,
Inc. at a purchase price of $22, 250,000. In combination, these two acquisitions
are  expected to add  approximately  $30 million in new annual  revenues.

About Prestige Brands

     Prestige Brands,  Inc. markets and distributes brand name  over-the-counter
drug, personal care and household products sold throughout the United States and
Canada. Key brands include Chloraseptic(R) sore throat relief products; Compound
W(R) wart remover;  New Skin(R) liquid bandage;  Clear eyes(R) and Murine(R) eye
care  products;   Little  Remedies(R)  pediatric   over-the-counter   healthcare
products;  Cutex(R) nail polish remover, Comet(R) and Spic and Span(R) household
cleaning products, and other well recognized brands.

     All  statements,  other than statements of historical fact included in this
release, are forward-looking  statements, as that term is defined in the Private
Securities Litigation Reform Act of 1995.  Forward-looking  statements generally
can  be  identified  by  the  used  of   forward-looking   terminology  such  as
"assumptions,"  "target," "guidance,"  "outlook," "plans,"  "projection," "may,"
"will,"  "would,"  "expect,"  "intend,"  "estimate,"   "anticipate,"  "believe,"
"potential,"  or  "continue"  (or the negative or other  derivatives  of each of
these terms) or similar terminology.  There are certain factors that could cause
actual  results  to differ  materially  from  those  anticipated  by some of the
statements made.  These include:  (1) the ability to achieve business plans; (2)
successfully  executing,  managing and  integrating  key  acquisitions;  (3) the
ability to manage and maintain key  customer  relationships;  (4) the ability to
maintain key manufacturing  and supply sources;  (5) the ability to successfully
manage regulatory,  tax and legal matters (including product liability matters),
and to resolve  pending  matters  within current  estimates;  (6) the ability to
successfully  manage  increases in the prices of raw materials  used to make the
Company's  products;  (7) the  ability  to stay close to  consumers  in a era of
increased media  fragmentation;  and (8) the ability to stay on the leading edge
of innovation.  For additional  information  concerning factors that could cause
actual results to materially differ from those projected herein, please refer to
our most recent 10K, 10Q and 8K reports.

Contact: Dean Siegal
914-524-6819

Primary IR Contact

Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819

Transfer Agent

AST
6201 15th Avenue
Brooklyn, NY 11219
Telephone: (800) 937-5449
help@astfinancial.com
https://www.astfinancial.com

Subscribe

Stay up to date with investor news, stock information and SEC filings.
Subscribe »